Carta Biosciences

Carta Biosciences, founded in 2018 and based in Cambridge, UK, is a private diagnostics company specializing in genomic testing for the IVF market. Its core innovation is a polygenic risk scoring (PGT-P) service, powered by a proprietary machine learning algorithm that analyzes whole-genome data to predict an embryo's lifetime risk for complex diseases like heart disease, diabetes, and breast cancer. The company integrates this with standard PGT tests (PGT-A, PGT-M, PGT-SR) into a single offering, aiming to give clinicians and parents a more comprehensive tool for embryo selection. Carta appears to be in an early commercial or late-development stage, targeting direct sales to IVF clinics.

Proprietary machine learning algorithm for polygenic risk scoring (PGT-P) applied to whole-genome sequencing data from embryo biopsies, integrated with standard PGT tests (PGT-A, PGT-M, PGT-SR).

Carta competes with established PGT companies like CooperGenomics, Natera, and Igenomix that offer PGT-A and PGT-M but not yet widely commercialized PGT-P. It is an early mover in branding a dedicated PGT-P service, but faces potential competition from both these incumbents and new startups as the field develops. The competitive arena is defined by clinical validation, regulatory clearance, and clinic relationships.